vTv Therapeutics(VTVT) - 2025 Q4 - Annual Results

Financial Performance - vTv's cash position increased to $88.9 million as of December 31, 2025, compared to $36.7 million as of December 31, 2024[7]. - The net loss attributable to vTv shareholders for Q4 2025 was $7.1 million, or $0.58 per basic share, compared to a net loss of $3.6 million, or $0.55 per basic share, in Q4 2024[7]. - For the full year 2025, net loss attributable to vTv shareholders was $27.0 million, or $3.20 per basic share, consistent with the loss per share from the previous year[7]. Research and Development - Research and Development (R&D) expenses for Q4 2025 were $3.9 million, up from $2.2 million in Q4 2024, primarily due to increased spending on cadisegliatin[7]. - The company initiated patient dosing in the Phase 3 CATT1 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes[2]. - The company submitted a Phase 2 clinical study protocol for cadisegliatin in type 2 diabetes to the UAE Department of Health in December 2025[3]. - vTv expanded its intellectual property estate supporting cadisegliatin during 2025[2]. Clinical Trials and Enrollment - The company expects to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026, with enrollment momentum accelerating due to expanded site participation and increased engagement efforts[2]. - The Phase 3 topline data is expected to have a substantial effect on the company's performance and revenue projections[16]. Strategic Outlook - The company anticipates that the expected use of proceeds from the offering will significantly impact its future operations and financial position[16]. - The company emphasizes the benefits of cadisegliatin for individuals living with Type 1 Diabetes (T1D) as a key part of its strategy[16]. - Future revenue and projected costs are subject to known and unknown risks, which may lead to actual results differing from expectations[16]. - The company acknowledges that its forward-looking statements do not account for potential impacts from future acquisitions, mergers, or joint ventures[16]. Licensing Agreement - vTv Therapeutics received $20.0 million in February 2026 from Newsoara under an amended licensing agreement[1].